Theralase End of Quarter Sale of Therapeutic Lasers

Theralase Opens New Head Office and Therapeutic Laser Centre

Toronto, ON – May 28, 2013 - Theralase Technologies Inc. (TSX-V: TLT), announced today the launch of its new head office and multidisciplinary therapeutic laser centre in the heart of the Beach District of Toronto, Ontario. The new laser centre will provide local patients with a proven, highly effective, non-invasive treatment to address painful and inflamed medical conditions, without the need for surgery or pharmaceutical drugs, and their associated side effects. 

“The Centre will be a multidisciplinary pain and rehabilitation treatment centre focused on delivering Theralase therapeutic laser therapy treatments through mainstream medical practitioners, such as: medical doctors, chiropractors, physical therapists, naturopathic doctors, doctors of podiatry and registered massage therapists,” said Dr. Rhonda Mostyn, Clinic Director of Theralase Therapeutic Laser Centre.  “Our initial focus will be primarily chronic and acute pain caused by neural muscular skeletal conditions, sports injuries, motor vehicle accidents or trauma, but as the centre grows, we may branch out into other disciplines such as wound healing and addiction.”

“With regards to our growing number of customers, the new training facility will provide state of the art conferencing technology and training sessions on our cutting-edge technology, laser therapy certification courses and the latest treatment protocol optimization support,” said Roger Dumoulin White, President and CEO of Theralase Technologies. “The new corporate head office, in addition to housing executive management, finance, sales and marketing functions will also support an ISO-13485 certified, Health Canada, FDA and CE approved facility to manufacture the Theralase line of therapeutic lasers, as well as aftermarket sales and service support for all of Theralase’s healthcare customers. Thousands of satisfied healthcare practitioners and patients throughout North America attest to the safety and effectiveness of Theralase’s laser technology. We expect the laser centre to be very successful in the near term adding a significant revenue stream to the Company.”

The corporate head office and therapeutic laser centre will now be located at, 1945 Queen Street East, Toronto, Ontario, Canada, M4L 1H7, Phone: 416-699-LASE (5273), Toll-free: 1-866-843-LASE (5273), Fax: 416-699-5250, and will be open from 7:00 am to 7:00 pm 7 days a week to fully service our local patients and our international sales team.

About Theralase Technologies Inc.:

Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neuro musculoskeletal conditions and wound healing. Theralase is currently developing proprietary Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technology.

 For further information please visit www.theralase.com , regulatory filings may be viewed by visiting www.sedar.com.

 

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information:

Roger Dumoulin-White                                                                     

President & CEO                    

416-699-LASE (5273) ext. 225                                   

rwhite@theralase.com 

Theralase Therapeutic Laser Centre Now Open!

THERAPEUTIC LASER CENTRE

  GRAND OPENING!

Offering Complimentary Consultations until June 30th

We are a full service clinic offering treatments for:

Muscle pain                          Sports Injuries

Joint Pain                              Arthritis

Shoulder Injuries                  Knee Pain

Tendinitis                              Neck and Back Injuries

Headaches                           Plantar Fasciitis

Carpal Tunnel/Wrist Pain     Foot Pain

Services Include:

·       Cold Laser Therapy

·       Chiropractic

·       Massage Therapy

·       Assessments and Treatment Programs

Cold Laser Therapy is a non-invasive, comfortable, proven treatment for the relief of pain, reduction of inflammation and repair of damaged tissues.

No referral required.

Services may be covered by private insurance plans.

Located at 1945 Queen Street East, Toronto, Ontario

Phone: 416-699-5273

www.theralase.com

What is Cold Laser Therapy?

Cold laser treatment methods is a somewhat innovative technology when compared to the a great number of alternative therapies such as acupuncture (that's been practiced since 8000-3500 B.C.), chiropractic (since 1895) as well as physical therapy. Just like the abacus evolved into the computer, a variety of alternative medicine practices are expanding to also include light therapy. More recent advancements in low-level lasers now make it possible for the average medical professional or individual to own cold laser equipment. Cold lasers are sometimes called Low Level Lasers (LLL) or soft lasers.

Cold Laser treatment offers a non-intrusive option to acupuncture and surgery. It additionally allows for a non-addicting treatment which usually eliminates the complications associated with long-term medication treatment programs. Cold lasers tend to be commonly utilized for treatment associated with: Acute and chronic joint pain, Tendon strains, Muscle strain, Soft tissue injuries, Tendonitis, Arthritis, Tennis elbow, Back soreness, Bursitis, Carpal Tunnel Syndrome, in addition to Fibromyalgia.

In general, cold lasers usually are implemented in 2 specific methods. One is in fact Targeting acupuncture trigger points (analogous to acupuncture however minus the needles) and the other is actually by using Wide coverage of deep tissue with laser photons in order to spark changes within the tissue.

The cold laser creates an impulse of light at a specific wave length (typically 905nm) which will diminishes reflection in addition to scattering but maximized absorption of the energy (in photons) at a desire depth.

Various conditions such as joint pain involve a deep penetration (4-5 inches) that can only be accomplished using a super-pulsed laser emitter. Many systems also contain other lower wavelengths in addition to lower-power emitters for treating shallow tissue (like the lymph system or even surface scars). In addition, red light diode with a wave length of 660 nm could be utilized to add energy to even shallower levels of tissues. It is definitely the over-all judgement that wavelengths less than 660 nanometers are usually very easily absorbed within the surface tissue and are not optimized pertaining to deep tissue healing.

The purpose of laser therapies is to provide light energy units via infrared laser radiation, referred to as photons, to damaged cells. It is the preference of industry experts is that photons absorbed by the cells by way of laser therapy stimulate the mitochondria to boost production of ATP. This specific biochemical increase in cell energy can be utilized to enhance live cells from a state connected with illness to a stable, healthy state.

About 4000 reports have actually been performed in recent years to actually validate the effectiveness regarding cold laser therapies. The following actually are some of the particular advantages connected with Cold Laser Therapies. The therapy is definitely simple to implement, very safe, non-toxic, non-invasive, zero side effects or discomfort, cost effective with regard to both the practitioner and patient, particularly effective in treating ailments (more than 90% efficacy), superior alternative to pain killers, reduces the need regarding surgery, and often will work synergistically along with other modalities such as Chiro, Acupuncture, as well as Rehabilitation.

At this time, lasers are employed substantially in the medical industry intended for everything from cosmetic surgery, eye surgery and also heart surgery. The particular ability to place merely the right amount of energy straight into a vital spot of the human body is a fantastic advancement throughout the medical field. Cold lasers are usually an essential addition to these various other established medical laser treatments and the recent development involving  professional cold lasers suggests that cold laser therapy will probably be a rapidly growing non-invasive medical treatment option.

For more information please call 1-866-843-5273 or visit www.theralase.com 

Theralase Announces 2012 Year End Financials

Theralase Advances Therapeutic Laser and Cancer Destruction Technologies

Toronto, Ontario – May 1, 2013, Theralase Technologies Inc. (TSXV: TLT) announced its year end 2012 financial results today.

Total revenue for the twelve month period ended December 31, 2012 dipped slightly to $1,824,313 compared to $2,027,058 for the same period in 2011, a 10% reduction, primarily due to a reduction in laser sales in the US and internationally. In 2012, Theralase focused its efforts on laser sales in Canada for its Therapeutic Laser Technology (TLT) Division and for accelerating the research and development of its patented cancer destruction platform for its Photo Dynamic Therapy (PDT) Division.

Selling expenses decreased by 41%, to $626,380 for the twelve month period ended December 31, 2012 compared to $1,060,288 for the same period in 2011. The percentage decrease was due to decreased spending on salaries, marketing, advertising and travel related expenses, as more focus was paid to completing sales in Canada, than abroad. 

Administrative expenses increased from $1,028,431 for the twelve months ended December 31, 2011 to $1,238,900 for the same period in 2012 representing an increase of 20%. The increase in administrative expenditures was primarily due to increases in the costs associated with stock based compensation.

Research and development costs increased to $873,335 for the year ended December 31, 2012 compared to $759,352 for the previous year, representing a 15% increase, due in part to the costs required to commercialize the TLC-2000 biofeedback laser, but primarily due to research and development costs of the TLC-3000 Photo Dynamic Compound (PDC) cancer and bacteria destruction technology.

The net loss for the year ended December 31, 2012 was $1,509,569, which included $322,915 of net non-cash expenses (amortization, stock-based compensation expense, foreign exchange gain/loss, equipment write-off and lease inducements) compared to a net loss in 2011 of $1,453,974, which included $74,921 of net non-cash expenses.  The increase in net loss is due to  increases in the costs associated with stock based compensation, commercialization of the patented TLC-2000 Biofeedback Therapeutic Laser due for launch in 2013 and primarily due to the research and development of the TLC-3000 Photo Dynamic Compound cancer destruction technology due for completion of the pre-clinical phase by 4Q2013.

Theralase has had many successes in 2012, specifically:

• Preclinical research that confirmed the complete destruction of subcutaneous (under the skin) colon cancer tumours in mouse subjects, which were treated with the Theralase anti-cancer Photo Dynamic Compound (PDC) technology, which have continued to thrive cancer-free for more than 1 year post-treatment without any side effects.
• Bladder cancer named as the principal cancer target
• Theralase’s PDC was found to be 100% effective in destroying bladder cancer tumour cells
• Theralase PDCs have shown an ability to destroy Escherichia Coli (E. coli) and Listeria Monocytogenes (Listeria) bacteria in vitro when light activated
• Theralase establishes laser distributors in the Middle East and China
• Addition of TENS (Transcutaneous Electrical Nerve Stimulation) on select laser models to allow additional CPT billing codes for the US market
• Theralase's innovative anti-cancer PDC technology validated at major international conferences
• Theralase expands intellectual property portfolio with increased patent protection
• Renowned oncologist Dr. Michael Jewett joins Theralase's medical and scientific advisory board

Roger Dumoulin-White, President and CEO of Theralase Technologies Inc. stated, “The Company has completed the research and development of its next generation, patented TLC-2000 Biofeedback Therapeutic Laser and is now preparing for its launch in 4Q2013. In addition, Theralase has made great strides forward in the research and development of its patented Photo Dynamic Compounds (PDCs), indicated for the destruction of specific cancerous tumours. Our first target, bladder cancer, should be ready for human trials as early as 2014. In order to capitalize on this state-of-the-art cancer destruction technology and dramatically increase shareholder value, Theralase is in negotiations with strategic partners focused on the early commercialization of this ground breaking technology.”

About Theralase Technologies Inc.

Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. As well, these applications extend to the care of animals by veterinarians. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary laser technology.

The complete consolidated financial statements and MD&A for twelve months ending December 31, 2012 may be viewed at www.theralase.com  and www.sedar.com .

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information, please contact:

Roger Dumoulin-White,                                                                              

President & CEO                                                                                           

416-699-LASE (5273) ext. 225                                                                                  

rwhite@theralase.com

Kristina Hachey

Chief Financial Officer

416-699-LASE (5273) ext. 224

khachey@theralase.com                                                                             

Greg Bewsh

Director of Investor Relations

416-699-LASE (5273) ext. 258

gbewsh@theralase.com   

Arkady Mandel

Chief Scientific Officer

416-699-LASE (5273) ext. 260

amandel@theralase.com

Cold Laser Therapy: Certificate Course Nov. 24th in Toronto

Trouble viewing this email? Read it online

TO REGISTER By email: Forward completed Registration form to rmostyn@theralase.com (After selecting 'Forward' you will be able to type into form) By Fax: Fax completed Registration form to 1.416.447.3020 By Phone: 1.866.843.5273 ext:243 Registration Form - Cold Laser Therapy: Certificate Course Name: Address: City: Province / State: Postal / Zip Code: Phone: E-Mail: Method of Payment Cheque (payable to Theralase Inc.) Visa: MasterCard: Amex: Credit card Number: Expiry Date:

Is TENS Just a Placebo for Chronic Pain?

From :Pain-Topics.org News/Research UPDATES

Recently reported research found that transcutaneous electrical nerve stimulation (TENS) was significantly helpful in reducing chronic pain intensity and disability while improving perceived health status for up to 1 year. However, these outcomes were comparable to those produced by sham/placebo TENS. Does this mean that TENS is worthless as a pain-treatment modality, or is there a need to reconsider the role and value of meaningful placebos in pain management?
TENS is an easy to use, noninvasive, analgesic intervention that may result in less pain, increased functionality, and decreased use of pain medication. Although TENS has been in use since the early 1970s, short-term results of this therapy have been inconclusive for treating chronic pain, and long-term randomized placebo-controlled studies with treatment periods of more than 3 months had not been executed. Therefore, researchers in The Netherlands designed a study to explore the long-term (1 year) time course of TENS treatment effects compared with a sham-TENS placebo [Oosterhof et al. 2012].
Writing in the September edition of Pain Practice they report a randomized placebo-controlled trial enrolling 163 patients with chronic pain who had been referred to a multidisciplinary pain center at a university hospital. Patients were being treated for peripheral neuropathic pain, osteoarthritis and related disorders, or injury of bone and soft tissue, and usual care for their conditions had failed in the past to satisfactorily ameliorate their pain.
Prior to randomization, all patients had their pain medication optimized by the attending anesthesiologist or pain practitioner; however, at baseline, the mean pain intensity among all patients was still moderate (about 62mm on a 100mm scale). Identical TENS devices were used for the actual and sham treatments, and self-applied by subjects for several hours each day. Sham units showed a fake output reading on the LCD display, but no current was delivered to the electrodes. The main endpoints of interest were the proportion of patients satisfied with treatment results and willing to continue treatment at the end of 1 year, pain intensity, pain disability, and perceived health status.
Results indicated that, throughout the time-course of the study, there was no significant difference (P=0.79) in the proportion of patients satisfied with actual vs. sham-TENS therapy; at the end of the year, an intention-to-treat analysis showed that 30% (24/81) of patients in the TENS group and 23% (19/82) of the sham-TENS group were satisfied with treatment results. These 43 patients in both groups experienced a mean overall improvement of 62.7%, and there were no significantly different between groups (P=0.74). Also, for patients still satisfied after 1 year, there were no differences in pain intensity or disability, perceived health status, or pain medication use between the TENS and sham-TENS groups; although, these measures in both groups had improved significantly from baseline.
COMMENTARY: Limitations & Possibilities
As noted above, TENS therapy has been in existence for nearly 4 decades. The TENS unit is a small, portable device delivering mild electrical current to nerves through electrodes connected to the skin at or near the sites of pain.
The approach has been used for various types of pain, although exact mechanisms of its analgesic effects are still under examination. Basic science studies suggest that TENS activates endogenous pain-control chemicals (eg, endorphins, enkephalins, dynorphins, GABA, serotonin) and their receptors. Along with that, the high and low electrical frequencies produced by a TENS unit inhibit pain signals along affected nerves, ostensibly blocking the impulses from reaching pain-perception areas in the brain.
In the Oosterhof et al. [2012] study, for those patients who appeared to respond to a TENS intervention and were satisfied with the therapy, there were stable improvements in pain and other measures over the 1-year period, whether they were assigned real or sham TENS units. However, as the authors concede, there was no third group for comparison receiving standard care without TENS to control for regression to the mean or the natural course of chronic pain, so they could not claim to have found a true placebo effect induced by the sham-TENS procedure.
During the year, 44 patients in the TENS group were lost to followup, with 18 dropping out due to dissatisfaction with treatment results. In the sham-TENS group, there were only 32 lost to followup, with 14 dissatisfied with results. Also, 93% of subjects in the actual TENS group but only 70% in the sham-TENS group believed they had received a real TENS unit, which should have decreased favorable placebo effects but did not.
The intervention was relatively safe, with the only adverse effect being that roughly half of all patients experienced skin problems caused by the electrodes, but only 4 (2 in each group) discontinued for this reason. Apparently, this was not due to actual electric current and the researchers noted that this problem can normally be overcome by changing the type of electrode.
The researchers note quite importantly that among those patients still satisfied with either actual or sham TENS after 1 year there was an average decrease of more than 50% in pain intensity, which is both statistically and clinically significant. Even among those who stopped treatment earlier, there was about a 28% improvement in pain, which may be clinically noteworthy since this went beyond the pain relief afforded them by usual medical care.
As one limitation, there may not have been a sufficient number of subjects completing the trial. The study design required 35% of patients in the TENS group and 15% in the sham-TENS group being successfully treated after 1 year to have 80% power for detecting significant difference between groups. Since these targets were not achieved, the lack of differences between groups might have been statistically a false negative, or Type II error.
Aside from that, in this long-term study by Oosterhof and colleagues [2012] it appeared that TENS might have functioned similar to placebo or, conversely, the sham/placebo treatment may have had genuine medical efficacy. As the researchers note, this may support the contention that “placebo effects are genuine psychobiological events, which can be robust in both laboratory and clinical settings.”
Along these lines, the researchers observe that, in neuropathic pain trials, placebos have had durable long-term effects that pose difficulties in distinguishing between treatment and placebo effects. Furthermore, other researchers [eg, Quessy and Rowbotham 2008] have noted that this problem is magnified in trials in which long treatment periods under blinded conditions are required and in which the analysis assigns trial dropouts as treatment failures, as in the Oosterhof et al. study.
TENS for Chronic Pain
Other research has investigated TENS for chronic pain. A Cochrane Systematic Review by Nnoaham and Kumbang [2008] compared “no treatment” controls with sham-TENS or active TENS using different electrical frequencies. Of 124 studies identified in their searches, only 25 RCTs (N=1,281) could be evaluated. At that, there was such a high degree of heterogeneity (differences and inconsistencies) across studies that a data meta-analysis was not possible.
Overall, in 13 of 22 sham/placebo controlled studies there was a positive analgesic outcome in favor of active TENS treatments. For multiple-dose treatment comparison studies, 8 of 15 were considered to be in favor of TENS therapy. Results were based on short-term low-volume TENS treatment: The duration of treatment was <4 weeks in about 80% of the studies, and in 70% of the trials treatment occurred <10 hours per week with 60% of the participants having <10 total sessions of TENS. The authors note that these limitations may explain why some of the studies failed to detect any differences between active TENS and sham controls.
Nnoaham and Kumbang conclude that published literature on TENS lacks the methodological rigor or robust reporting needed to make confident assessments of this therapy for chronic pain management. However, they assert that, even if the effect of TENS on chronic pain is a weak one, its potential to augment the effect of other pain treatment modalities should be explored. Indeed, in the much longer-term Oosterhof et al. study, TENS therapy was additive to analgesic effects of pain medications that all patients were taking.
TENS for Low-Back Pain
We have previously discussed in an UPDATE [here] evidence reviews and guidelines that found TENS ineffective for treating chronic low-back pain; although the evidence had some strong limitations that challenged its internal and external validity. Similarly, in 2008, a Cochrane Systematic Review by Khadilkar et al. examined 4 high quality RCTs of TENS for chronic back pain (585 patients) and found conflicting and inconsistent evidence, in comparison with placebo, to support the use of TENS. However, these studies were so disparate in design (clinical heterogeneity) that the researchers could not do a data meta-analysis and had to rely on qualitative observations that are prone to bias.
In response to the lack of clear and convincing evidence in support of TENS for chronic back pain, last summer the U.S. Centers for Medicare and Medicaid Services (CMS) announced it would no longer cover most uses of TENS for this pain condition [see MedPage Today article here]. They noted that reimbursement for TENS in treating low-back pain in particular will be available only when patients are participating in a randomized, controlled trial of the technology’s clinical effectiveness.
In the announcement they wrote, “TENS is not reasonable and necessary for the treatment of [chronic low back pain].” The CMS had conducted a review in the wake of a 2010 report by an American Academy of Neurology panel that, on the basis of only 5 trials, found the treatment was not effective [discussed in the abovementioned UPDATE]. Although, the CMS also acknowledged that some individual studies have shown that TENS can reduce pain and improve patients' physical function.
While the CMS plans to withhold coverage of TENS for chronic back pain, it will continue to fund RCTs of TENS for 3 years. The trials must directly address TENS’ clinical efficacy and be designed and powered to yield clear-cut answers. At present, the CMS emphasized that Medicare will still reimburse for TENS prescribed for treatment-resistant pain conditions other than low back pain, such as for chronic or severe postoperative pain.
When is a “Placebo” of Meaningful Value?
There are some interesting and remarkable parallels of research outcomes for TENS, as described above, with acupuncture for chronic pain in regard to the prominent influence of placebo effects as a possibly important component of therapeutic efficacy. Acupuncture was most recently discussed in an UPDATE [here], which noted that its benefits for treating musculoskeletal pain, osteoarthritis, and chronic headache were only weakly better than placebo, but that both placebo and true acupuncture conferred moderate benefits in reducing pain that went beyond and above the usual medical care patients had been receiving.
Both acupuncture and TENS have been available for a long time and there has been much research conducted to examine each modality; yet, the quality of most research has been surprisingly low and generally precludes an unbiased pooling of studies for more rigorous analyses. Despite this, it appears that both modalities have potential for offering select groups of patients nonpharmacologic options for pain relief and other health benefits; albeit, perhaps due largely to placebo components of the overall effects. And, as the Oosterhof et al. study demonstrates, the duration of those favorable effects can be long-lasting.
TENS is noninvasive and acupuncture is minimally invasive, both have relatively favorable safety profiles, and their benefit-to-cost ratios may be advantageous compared with some other therapies. Either therapy may be abruptly discontinued without adverse effects and, as the Oosterhof et al. study suggests, patients who do not benefit readily stop the treatment.
So, perhaps what is needed is a reconceptualization of the role of placebos in pain management and, when it comes to TENS or acupuncture, a recognition that a completely inert placebo version of these therapies may not exist.
As Andrew Avins, MD, suggested in an editorial discussed in our recent UPDATE on acupuncture, it may be time for an examination of why so many healthcare professionals feel threatened by the existence of placebo effects and, instead, consider how those effects might be harnessed for better pain care. Capitalizing on placebo effects may be perceived as bad science by some, but it may be welcomed as good medicine by patients who benefit.

Disclosure: We have no vested interests in or support from any manufacturers of electrical nerve stimulation devices, including TENS. Our only interest here is in arriving at sound practice decisions in pain management based on appropriately credible, reliable, and valid analyses of clinical evidence. — SBL

REFERENCES:
> Khadilkar A, Odebiyi DO, Brosseau L, Wells GA. Transcutaneous electrical nerve stimulation (TENS) versus placebo for chronic low-back pain. Cochrane Database of Systematic Reviews. 2008;4(CD003008) [abstract].
> Nnoaham KE, Kumbang J. Transcutaneous electrical nerve stimulation (TENS) for chronic pain. Cochrane Database of Systematic Reviews. 2008;3(CD003222) [abstract here].
> Oosterhof J, Wilder-Smith OH, de Boo T, et al. The Long-Term Outcome of Transcutaneous Electrical Nerve Stimulation in the Treatment for Patients with Chronic Pain: A Randomized, Placebo-Controlled Trial. Pain Practice. 2012(Sep);12(7):513-522 [abstract here].
> Quessy SN, Rowbotham MC. Placebo response in neuropathic pain trials. PAIN. 2008;138(3);479-483 [abstract here].

Cold Laser Therapy Seminar - Earn 6 CE Hours

2 Seminars to Choose from
Cold Laser (101) Introductory Seminar  3 CE Hours        Wednesday June 27, 2012 - 6:30 to 9:30pm You Will Learn: Introduction to Laser Biophysics  - Why and How Medical Lasers Work Laser Specifications - Why This is all That Matters and What is Best for your Clinical Practice  Laser Treatment Basics - Indications, Contraindications, Designing a Safe Treatment Room Speaker: Roger Dumoulin-White, PEng Mr. Dumoulin-White is the President and CEO of Theralase Technologies Inc. and has been involved in the research, design and manufacture of therapeutic medical lasers for the last 18 years. Cold Laser (102) Intermediate Seminar 3 CE Hours Thursday June 28, 2012 6:30 to 9:30pm You Will Learn: Treatments of Specific Musculoskeletal Conditions - Knee, OA, RA, Tendinitis, Adductor Strain, Lower Back Pain, Plantar Fasciitis and more. Hands on Workshop with Indepth Review of Clinical Case Studies Latest Published Clinical and Scientific Research on Cold Laser Therapy and Trends in the Research Speaker: Rhonda Mostyn, BSc, DC Dr. Mostyn is the Director of Clinical Services and Training at Theralase Laser Technologies		Location: Theralase Inc. 29 Gervais Drive Suite 102 (Don Mills and Eglinton) Toronto, Ontario M3C 1Y9 Cost (per seminar): $49 each ($99 each after June 19th) To Register: call 1-866-843-5273 email rmostyn@theralase.com Seating is limited! Reserve your Space Today!

How to Choose The Best Cold Laser For Your Practice

How to Choose The Best Cold Laser For Your Practice? How to Choose the Best Cold Laser for Your Practice Date: Wednesday, June 20th, 2012 Time: 1:00 PM - 2:00 PM EST   Below are a few items that will be covered in the Webinar:  Learn optimal wavelengths to heal deep tissue injuries.  Identify key features including power, treatment times, laser probes.  Understand the difference between LEDs and lasers and between class 3 and class 4 lasers.  Select a laser that meets the needs of your patients and practice TO REGISTER https://www2.gotomeeting.com/register/219059266 Regards, The Theralase Team Links www.theralase.com Theralase Laser Clinic Clinic Locator

SuperPulsed 9 Diode Cold Laser as Low as $5,000

Theralase SuperPulsed Therapeutic Laser as low as $5,000
All Theralase Therapeutic Lasers offer:
Features: Superpulsed 905nm technology 5 x 905nm & 4 x 660nm 4 different power levels  Options: Extended warranty available Service loaner program Benefits: Activates all 3 known cellular pathways Able to penetrate 4" into tissue Fast treatment times (<10 minutes total) Eliminates pain Reduces inflammation Accelerates tissue healing
Call 1-866-843-5273 or email sales@theralase.com Discover why Theralase is the safest and most effective therapeutic laser on the market.
www.theralase.com

Cold Laser Therapy: Biological Effects & Clinical Applications

TO REGISTER By email: Forward completed Registration form to info@theralase.com (After selecting 'Forward' you will be able to type into form) By Fax: Fax completed Registration form to 1.416.447.3020 By Phone: 1.866.843.5273 ext:243 Registration Form - Cold Laser Therapy: Certificate Course Name: Address: City: Province / State: Postal / Zip Code: Phone: E-Mail: Method of Payment Cheque (payable to Theralase Inc.) Visa: MasterCard: Amex: Credit card Number: Expiry Date:

Theralase Inc.
29 Gervais Drive suite 102
Toronto Ontario m3c1y9
Canada 

Chronic Pain: 1 in 3 Suffer, Study Says

By Delthia Ricks

Newsday

Persistent pain that lasts weeks to years is an overlooked medical problem that affects more than 116 million people nationwide and needs to be the focus of a public health campaign, doctors said this week.
Physicians reporting in the New England Journal of Medicine cited a long list of concerns, including lack of access to pain-management specialists and inadequate consumer education about pain treatment, that they believe is causing people to suffer needlessly.
Authors of the report are calling on the medical community to educate more doctors capable of treating people experiencing long-term, intractable pain.
“That’s like 1 in 3 Americans in pain and that estimate is not far off the mark, based on what I am seeing,” said Dr. Brian Durkin, director of the Center for Pain Management at Stony Brook (N.Y.) University Medical Center.
“It’s a little shocking when you think about 1 out of 3 people being in pain. But I am getting calls every day,” added Durkin. “People are not looking for narcotics; they’re looking for pain relief.”
Dr. Philip Pizzo, dean of Stanford University’s medical school, wrote the report, which is based on research he led last year as chairman of an Institute of Medicine panel. The institute is the health division of the National Academy of Sciences and is chartered by Congress to investigate health concerns.
Pizzo said round-the-clock acute and chronic pain affects adults and children, and that there is misunderstanding and insensitivity about persistent pain by physicians and the public.
With fewer than 4,000 pain specialists nationwide, Pizzo said it’s time for primary care physicians to step up and help address what he calls a nationwide epidemic.
Durkin said about 50 million people undergo surgery annually in the United States, and many of those patients account for those in acute pain.
The vast number of people who make up the millions in long-term discomfort generally suffer from persistent headaches, and neck and lower-back pain, he said.
“So 116 million is not that crazy a number,” Durkin said. “Our population is getting older, and people are having problems.”
Dr. Lewis Nelson, an emergency medicine specialist and clinical toxicologist at New York University Medical Center in Manhattan said he doesn’t buy the estimate that nearly 1 in 3 Americans are in pain. He also doesn’t think there’s a shortage of pain management specialists.
“If there is so much pain, why are we just now finding out about it? Why weren’t people in pain 25 years ago?” Nelson asked.
Nelson said the estimate of millions of people in chronic pain is not only overblown, it overlooks the epidemic of prescription painkiller abuse. He said the pain epidemic can be plotted along a graph that also shows a rise in the worldwide proliferation of narcotic pain pills.
Nelson said he too often sees the flip side of pain treatment: people who have overdosed on prescription pain medication.
“To say that people in pain are not being treated overlooks those who are being overmedicated — and dying,” he said.


What can be done?

Benefits of Laser Therapy

Efficacy rates up to 90% with no side effects 
• Non-toxic
• Decrease/eliminate pain
• Reduce inflammation
• Promote new blood vessels and tissue growth
• Promote nerve axon growth
• Faster wound healing and closure
• Virtually painless
• Non-invasive
• Highly effective for patient (>90% efficacy) No side effects
• Drug free
• Extremely safe
• Easy to apply
• Cost effective for practitioner and patient
• Superior alternative to analgesics, NSAID's,
  other medications and other modalities
• Virtually no contraindications

For more information please call 1-866-843-5273 or visit www.theralase.com

Read more here: http://www.miamiherald.com/2012/02/07/2628037/chronic-pain-1-in-3-suffer-study.html#storylink=cpy#storylink=cpy